Direct to Consumer Pharmaceutical Advertising (DTCPA) benefits patients.

Tuesday, February 19, 2013 - 6:30pm

The motion: "This house believes that Direct to Consumer Pharmaceutical Advertising (DTCPA) benefits patients."

Should pharmaceutical companies be allowed to conduct branded and unbranded advertising directly to patients? Does the patient ultimately benefit from DTCPA when the bottom line of pharmaceutical companies is to drive sales of their products?

Find out next week what MBiotech students think.
 
For the motion: Team PentaGenex
 
Against the motion: Team NovaMentis
 
Hosts: Ingenia Healthcare Solutions

Tuesday, February 19th, 2013, 6.30pm-8.00pm.  Instructional Centre, Room 120.  Open to the public.

The Master of Biotechnology Program would like to thank AstraZeneca Canada Inc. for their continued support of this seminar series